iTeos Therapeutics is a privately held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of people with cancer by designing and developing best-in-class immunotherapies.
The Company has advanced EOS100850, an insurmountable, highly-selective and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I clinical trial in January 2019.
iTeos’s second clinical program, a fully human, ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in the second half of 2019.
Headquartered in Cambridge, MA with its R&D team based in Gosselies, Belgium, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011.
In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital, Curative Ventures, and SFPI. All previous investors also participated.